These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38477751)

  • 1. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
    Jeka S; Dokoupilová E; Kivitz A; Żuchowski P; Vogg B; Krivtsova N; Sekhar S; Banerjee S; Schwebig A; Poetzl J; Body JJ; Eastell R
    J Bone Miner Res; 2024 Apr; 39(3):202-210. PubMed ID: 38477751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
    Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
    Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
    Jamshidi A; Vojdanian M; Soroush M; Akbarian M; Aghaei M; Hajiabbasi A; Mirfeizi Z; Khabbazi A; Alishiri G; Haghighi A; Salimzadeh A; Karimzadeh H; Shirani F; Fard MRH; Nazarinia M; Soroosh S; Anjidani N; Gharibdoost F
    Arthritis Res Ther; 2022 Jun; 24(1):161. PubMed ID: 35773713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial.
    Singh I; Jose V; Patel R; Arora S
    Indian J Pharmacol; 2021; 53(1):6-12. PubMed ID: 33975993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.
    Reginster JY; Czerwinski E; Wilk K; Borowy P; Strzelecka A; Budlewski T; Janowska-Maus M; Szymanowski K; Kwiatek J; Postol S; Põder A; Supronik J; Kim S; Suh J; Han N; Kim N; Bae S; Silverman SL
    Osteoporos Int; 2024 Jul; ():. PubMed ID: 39042292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.
    Zhang H; Gu JM; Chao AJ; Cheng Q; Teng DH; Yu JM; Wang BW; Huo YN; Mao L; Zhang Q; Yang H; Yan SG; Zhang KQ; Zhao XL; Lin H; Pei Y; Yuan Z; Dai RC; He L; Chen L; Su YF; Deng ZL; You L; Ban B; Zhu M; Cao YL; Zhu YK; Li ZJ; Zhang Z; Yi CQ; Lu YB; Wang G; Han CC; Wang ZJ; Li XX; Zhang ZL
    Acta Pharmacol Sin; 2023 Feb; 44(2):446-453. PubMed ID: 35896694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.
    Gu J; Zhang H; Xue Q; Wang L; Cheng Z; Zhang Y; Li Q; Yuan L; Li Y; Dong J; Huo Y; Tang X; Hu L; Wang X; Hua F; Shen L; Cheng J; Zhou H; Xu Y; Yang T; Wang C; Xu J; Shen J; Zhang Y; Zhang X; Hong D; Guan X; Xiao X; Wang G; Liu Y; Fu L; Chen J; Cheng X; Ding Y; Liu L; Yao Q; Zhang X; Li L; Zhang P; Deng C; Jiang C; You L; Wang K; Zhang S; Xiao J; Liu W; Du X; Shang X; Pan T; Lei C; Guo S; Zhang Z
    J Orthop Translat; 2023 Jan; 38():117-125. PubMed ID: 36381249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis.
    Jiang Y; Huo Y; Li Y; Kong X; Wang B; Liu F; Zheng X; Li Y; Yang Y; Xu Y; Xue Q; Hu Z; Xiao Y; Ma W; Guo Y; Yu W; Xia W
    Expert Opin Biol Ther; 2024 Jul; 24(7):665-672. PubMed ID: 38752402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
    Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
    Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
    Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
    Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
    Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
    Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.
    Li H; Huang Y; Chen Z; Zeng A; Zhang H; Yu Y; Wei S; Li Q; Wang X; Wang X; Wang X; Yang R; Dai X; Bi M; Sun T; Zhang Q; Han C; Li Y; Kang X; Liu Y; Zhang L
    BioDrugs; 2023 Mar; 37(2):259-269. PubMed ID: 36802320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
    Khan AA; AbuAlrob H; M'Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S; Romanovschi M; Mehmood S; Zariffeh H; Guyatt G; Ibrahim Q; Brignardello-Petersen R; Syed HI
    Endocrine; 2023 Jun; 80(3):647-657. PubMed ID: 37186270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.